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of prion disease
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Variant Creutzfeldt-Jakob disease (vCJD) is a fatal neurodegenerative disorder characterised by 
accumulation of pathological isoforms of the prion protein, PrP. Although cases of clinical vCJD are 
rare, there is evidence there may be tens of thousands of infectious carriers in the United Kingdom 
alone. This raises concern about the potential for perpetuation of infection via medical procedures, 
in particular transfusion of contaminated blood products. Accurate biochemical detection of prion 
infection is crucial to mitigate risk and we have previously reported a blood assay for vCJD. This assay 
is sensitive for abnormal PrP conformers at the earliest stages of preclinical prion disease in mice 
and precedes the maximum infectious titre in blood. Not only does this support the possibility of 
screening asymptomatic individuals, it will also facilitate the elucidation of the complex relationship 
that exists between the ensemble of abnormal PrP conformers present in blood and the relationship 
to infectivity.
Creutzfeldt-Jakob disease (CJD) is an incurable neurodegenerative disorder characterised by the accu-
mulation of pathological isoforms of the prion protein, PrP1,2. CJD may arise sporadically or be acquired 
through exposure to prions via contaminated surgical instruments or infected tissue, including dietary 
exposure to bovine spongiform encephalopathy (BSE) agents resulting in variant CJD (vCJD)3. As a 
consequence of widespread exposure to BSE prions via the UK food chain, it is thought that as many 
as 1 in 2000 of the population may be carriers of abnormal PrP isoforms4. Significant questions remain 
over the link between observation of these protein deposits in lymphatic tissue and the likelihood of 
developing vCJD, given that the relationship between infection in the lymphoid system and the brain is 
not clear and that the incubation period of the disease can be decades5,6.
The possibility that there are silent carriers of vCJD within the population is a cause for concern not 
only for the individuals affected but also because of the potential for perpetuation of vCJD infection 
via medical and dental treatments, particularly the transfusion of contaminated blood products. Several 
animal studies have demonstrated that prion transmission can occur by blood transfusion7,8 and that this 
is an extremely efficient route of infection9. Experimental observations have been echoed by confirmed 
secondary vCJD infections in humans who received blood products from apparently healthy donors who 
later developed prion disease10–12. This strongly suggests the presence of vCJD infectivity in blood and 
therefore the need for precautionary measures to prevent further infections, ideally to include testing for 
prion infection as recommended by the recent UK House of Commons Science and Technology Select 
Committee enquiry into vCJD.
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The introduction of a validated screening assay for sub-clinical vCJD carriers would offer signifi-
cant protection but presents two major challenges. Firstly, the unavailability of samples from individuals 
known to be sub-clinical carriers of vCJD with which to validate any assay and secondly, the need to 
detect very low (in the femtomolar range) concentrations of prions that are likely to be found in the 
blood in the preclinical phases of disease13.
To address the first concern animal models of prion disease provide the only means by which pre-
clinical samples can be generated. Models previously employed have typically used sheep experimentally 
infected with either scrapie14 or BSE8 to obtain appropriate samples which have confirmed that blood and 
blood components are infectious in asymptomatic stages of disease. The majority of analyses have utilised 
protein-misfolding by cyclic amplification (PMCA)15,16 to achieve qualitative detection of abnormal PrP. 
However, there have been notable examples of bioassay in sheep yielding the important conclusions that 
all components of blood are infectious8, in particular white blood cell fractions14, and that transfusion 
leads to a greater risk of infecting a host than direct inoculation into the central nervous system9.
Although the use of sheep models allows the handling and experimental transfusion of whole units of 
blood and fractionated products to assess the impact and relevance of blood processing protocols, such 
experiments are extremely time consuming with incubation periods for disease measured in years and 
with associated high costs. Importantly, for all large animal experiments, and indeed conventional rodent 
bioassay, quantitative information is difficult to obtain.
To address the question of whether the Direct Detection Assay (DDA) has a sensitivity appropriate for 
the detection of carrier states we chose to study wild-type CD-1 mice experimentally infected with the 
Rocky Mountain Laboratory (RML)17 strain of prions for which there are rapid, high precision quanti-
tative cell-based assays for infectivity18. Whole blood was taken from these animals at various stages of 
disease incubation and compared with that taken from uninfected healthy controls using two assays, the 
DDA, which detects the presence of disease-specific, abnormal PrP conformers, and the Standard Steel 
Binding Assay (SSBA)18 which allows quantification of infectivity. The SSBA has been demonstrated to 
be 100-fold more sensitive than conventional rodent bioassay with the ability to detect RML-infected 
brain diluted 1010-fold, corresponding to a prion concentration less than or equivalent to 1 intracranial 
LD50 units/ml.
The DDA is a highly sensitive assay that utilises a solid-state binding matrix to capture and concen-
trate disease-associated prion proteins which are then detected immunologically19. The analytical sensi-
tivity of DDA for vCJD is equivalent to a 1010–fold dilution of vCJD prion-infected brain when diluted in 
blood. This corresponds to a diagnostic sensitivity to patient samples of 71%, whilst being 100% specific 
for prion disease20. The lack of any samples from known sub-clinical patients has prevented us from 
determining if these assay characteristics are sufficient for preclinical detection. Here we describe the 
application of both DDA and SSBA to blood samples taken from wild-type CD-1 mice at defined time 
points throughout the incubation period for prion disease.
Analytical sensitivity with DDA was slightly lower than we have previously reported for human sam-
ples19 and yet was sufficient to detect infection at all time points of incubation tested. Not only were we 
able to demonstrate the ability to qualitatively detect the relatively low levels of abnormal PrP conformers 
associated with sub-clinical infection, but by use of the SSBA we were able to quantify the infectious titre 
in our samples. Combined use of DDA and SSBA allows us to begin to understand the complex relation-
ship that exists between infectious titre and the wider ensemble of detectable abnormal PrP conformers 
associated with prion infection.
Results
Identification of prion infected rodent blood samples. We have previously described a blood-
based assay capable of detecting abnormal isoforms of PrP associated with vCJD infection19 that has a 
nominal specificity of 100%20. The established performance characteristics of the assay make it poten-
tially suitable for adaptation to screening applications such as testing donated blood units. One uncer-
tainty has been the ability of the assay to detect preclinical infection with prion disease and the paucity 
of samples from known carriers of vCJD has made this impossible to determine directly. By using the 
RML strain of rodent prions in mice we can generate samples from defined time points throughout the 
incubation period for disease and verify the level of DDA-reactive material in blood is sufficiently abun-
dant for detection prior to the onset of clinical disease.
To establish assay sensitivity for RML prions we created exogenous spiked materials comprising RML 
prion-infected brain in whole blood from wild type (CD-1) mice. Infected samples could be clearly dis-
tinguished from control blood (Fig. 1) at a dilution of at least 109-fold of brain (p = 0.02, unpaired t-test, 
two-tailed with Welch correction) a detection limit very similar to that we have previously determined 
for vCJD samples19. This limit of detection is sufficient for the diagnosis of patients and appropriate for 
use in public health risk assessment20.
Examination of whole blood taken from wild-type CD-1 mice and Tga20 transgenic mice21, that 
overexpress murine PrP, infected with the RML prion strain at clinical end point as well as from hamsters 
infected with Sc237 prion strain was conducted by comparing to their relevant non-infected controls. 
The prion infected blood samples were examined at three different blood to buffer ratios, i.e. 1:1, 1:10 
and 1:100 (Fig.  2). In each case the mean chemiluminescence signals from the prion-infected blood 
samples were significantly higher than those taken from healthy controls at an optimal blood to buffer 
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ratio (p value < 0.05, unpaired t-test, two-tailed with Welch correction). The ratio of blood to buffer mix 
required to observe the maximum differential between infected and control samples was determined to 
be different for each of the prion strains examined and did not follow a predictable dose response – a 
phenomenon we have previously observed. The ratio of blood to buffer needed to allow differentiation 
between RML-prion infected blood from healthy controls for both CD-1 and Tga20 mice was 1:10, 
whereas Sc237-prion infected hamster blood required a 1:1 ratio. Differences in chemiluminescense sig-
nals between experiments can be attributed to the heterogeneous nature of blood samples and to minor 
variations in materials and instrumentation that influence the magnitude of the arbitrary chemilumi-
nescense values recorded on any given day.
Detection in preclinical blood samples. To address the feasibility of detecting prion infection in 
sub-clinical states using the DDA, blood samples were taken from RML-prion infected mice at regular 
intervals through the incubation period until onset of clinical disease and compared to blood samples 
from non-infected control animals. Groups of ten CD-1 mice were inoculated intra-cerebrally with 1% 
w/v RML-prion infected end-point brain homogenate. Animals were then culled and blood samples 
taken at 20 day intervals post inoculation until the clinical end point of 157 (+ /− 8) days was reached. 
Blood samples from mice at each of the time points were pooled and analysed against healthy controls 
using the DDA (Fig. 3). Samples were analysed in triplicate in each of four independent assay runs. The 
mean chemiluminescence signals from each of the blood samples taken at 20 day intervals post inocula-
tion had a ratio to cut-off (mean of control plus 3× standard deviations from the mean) greater than 1. 
Thus it is possible to differentiate preclinical infection in CD-1 mice infected with RML-prions through-
out the incubation period and as early as 20 days post inoculation (dpi). The peak ratio to cut-off of 1.88 
(+ /− 0.09) is observed in blood samples taken from mice 140 dpi, and is elevated relative to the signals 
obtained immediately prior at 120 days and at clinical end point (p < 0.05, unpaired t-test, two-tailed 
with Welch correction). A similar pattern of infectivity changes with time was observed with a distinct 
increase in infectious titre immediately prior to the onset of a clinical syndrome (Fig. 4B). The basis for 
this is not clear but may result from a sudden deterioration of the blood-brain barrier (BBB) releasing 
material into the bloodstream and periphery (Fig.  5), which is then diluted and cleared resulting in a 
return to previous levels.
Detection of prion infectivity in blood prior to onset of clinical disease. To investigate the 
relationship between DDA signals and the quantitative detection of infectivity in these samples, blood 
taken from the time course incubation were also analysed using the SSBA. The SSBA utilizes the bind-
ing of prion infectivity to steel in combination with the highly prion-susceptible cell line PK1. It has a 
dynamic range of 6 logs and a sensitivity to 0.0029 (+ /− 0.002) TCIUw 18 or less than 0.5 LD50 units/ml22. 
The level of infectivity measurable in the blood of these animals steadily increased with time, maximum 
titres being observed at 140 dpi, approximately 20 days prior to clinical end point of disease (Fig. 3), in 
close agreement with previously published results23,24. Remarkably, infectivity was clearly detectable at 
the earliest time point of 20 dpi, with a titre equivalent to 2.3 (+ /− 0.85) LD50 units/ml. The detectable 
Figure 1. The detection limit for exogenous RML infection. A 10% w/v RML-prion infected brain 
homogenate was logarithmically diluted into whole blood collected from wild-type CD-1 mice down to 10−9 
and analysed by DDA. Mean chemiluminescence signals with standard errors of the mean (SEM) are shown 
for two independent experiments with n = 3 for each experiment. The signal arising from the whole blood 
diluent alone is shown as a background control (C).
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titre of prion infectivity was found to rise with time to a maximum of 49 (+ /− 1.93) LD50 units/ml of 
blood of mice at 140 dpi. This finding of approximately 50 LD50 units/ml of prion infectivity in rodent 
blood is in close agreement with previous studies which estimated the prion titre in blood using rodent 
bioassay25–28. In common with the detection of abnormal PrP by DDA described above, this spike in 
infectivity occurred prior to the onset of clinical signs and levels returned to 14.9 (+ /− 2.1) LD50 units/
ml in blood samples from mice at the clinical end-point of disease.
Integrity of the blood-brain barrier over a time course following RML inoculation. The con-
centration of matrix metalloproteinase 9 (MMP-9) in serum is a potential indicator of BBB integrity29–32, 
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Figure 2. Discrimination of endogenous rodent infected blood from normal controls. Data shown are 
the mean chemiluminescence signals (arbitrary units) of pooled blood samples from prion-infected rodents 
at clinical endpoint (dark bars), compared to the mean signal from normal controls diluted (light bars). 
Blood samples were analysed at three dilution ratios to capture buffer; 1:1, 1:10 and 1:100. Panels (A,B) 
show signals from blood taken from CD-1 mice and Tga20 mice infected with RML prions compared to 
healthy controls, respectively. Panel (C) is data obtained from blood taken from Syrian hamsters infected 
with Sc237 prions compared to controls. Error bars represent the standard deviation from the mean signals 
(n = 3).
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with elevated concentrations indicating breakdown or increased permeability. Blood from the same 
groups of CD-1 mice analysed by DDA and SSBA were assayed for the concentration of MMP-9 using 
the commercial Mouse Total MMP-9 ELISA kit (Molecular Probes). Analysis of whole blood from 
RML-inoculated mice at 20 dpi demonstrated the presence of 152 (+ /− 6.7) ng/ml of MMP-9 compared 
to 94 (+ /− 12.5) ng/ml in uninoculated controls. The concentration of MMP-9 was observed to reduce 
with time until 120 days post inoculation (dpi) to 54 (+ /− 12.1) ng/ml, after which point the concen-
tration increased to 125 (+ /− 13.7) ng/ml at 140 dpi and 122 (+ /− 10.1) ng/ml at the clinical point of 
disease (Fig. 4). The results are consistent with a breakdown of the BBB late in the incubation period, 
occurring at around 140 dpi or > 85% of the incubation period.
Correlation of DDA signal, levels of MMP-9 and infectivity in blood from RML prion-infected 
mice during incubation period to onset of clinical disease. In an attempt to gain insight into the 
progression of prion disease via rodent models and to understand how signals observed in our prototype 
human blood test (DDA), relate to prion infectivity found in blood, we correlated data obtained for each 
of the assays. It was found that there is a direct correlation between signals observed in the DDA assay 
and the level of MMP-9 in blood of RML inoculated CD-1 mice taken at 20 day intervals throughout 
the duration of disease until end point (P < 0.05; Pearson correlation, two-tailed test). However, neither 
the DDA signals nor the MMP-9 concentration in blood correlated with the measurable prion infectivity 
titre found in these blood samples as determined by the SSBA. However, detectable prion infectivity as 
determined by the SSBA analysis does show a significant positive correlation with time (Pearson corre-
lation with p < 0.05), increasing throughout the incubation period.
Discussion
The ability to accurately diagnose prion infection using biochemical methods is crucial to protect public 
health from iatrogenic transmissions, particularly arising from the transfusion of contaminated blood 
and blood products10–12,33. In the United Kingdom (UK) measures taken to prevent secondary infec-
tions of vCJD have included leucodepletion of donor blood, sourcing of plasma from non-UK sources, 
exclusion of transfusion recipients from donation, use of recombinant clotting factors for patients with 
bleeding disorders and ceasing the use of UK plasma for fractionation and export34. We have previ-
ously reported the development19 and validation20,35 of a blood test for vCJD based upon the detection 
of abnormal disease-specific isoforms of PrP, which is now in clinical use for the diagnosis of prion 
disease. The wider application of this test, or indeed other emerging assays36,37, for screening asympto-
matic individuals for potential infection is confounded by an inability to confirm that an assay detection 
limit is sufficient for the detection of preclinical infections. This problem arises as there are currently 
no samples available from individuals confirmed as sub-clinical carriers of vCJD with which to assess 
either the prevalence of prionaemia in BSE prion-exposed populations or the sensitivity of any potential 
blood tests. A definitive answer will require prolonged longitudinal study of individuals testing positive 
to determine what proportion of patients with vCJD prionaemia go on to develop clinical vCJD and how 
many are chronic carriers38.
Figure 3. Detection of infection in preclinical blood samples. DDA signals from pooled blood samples 
taken at 20, 40, 60, 80, 100, 120, 140 dpi and clinical end-point (EP) from CD-1 mice infected with RML 
prions. Samples were analysed in triplicate in each of four independent assay runs. Data are shown as the 
mean chemiluminescent signal ratio relative to a cut-off (error bars indicating SEM) determined from the 
mean + 3× SD of control non-infected blood samples.
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It has been suggested that carriers would have lower concentrations of abnormal PrP compared to 
individuals with clinical CJD13, and this seems likely. Despite potentially lower levels, animal models 
indicate clear preclinical blood involvement23,24,39,40 and very efficient transmission of prion infection 
has been demonstrated from blood taken from sheep in early preclinical stages of scrapie9. The use of 
the RML-prion strain allows rapid and precise estimates of low prion titre using cell-based assays41,42. 
Previous attempts to detect infectivity in low titre sources have required either the use of large num-
bers of recipient animals or the transfusion or large volumes of infected analyte in large animals. By 
using the SSBA18 we have not only verified but accurately quantified the presence of infectivity in blood 
even at the earliest stages of preclinical prion disease. A comparison of RML-infected brain diluted into 
either FVB/N-Prnp0/0 brain homogenate or blood showed that although the presence of whole blood 
impacted on the overall detection limit of the assay, it remained capable of detecting RML prions at 
concentrations of less than 1 LD50 units/ml. Infectivity was found to rise by approximately 10–20-fold 
throughout the incubation period (Fig. 4) as might be anticipated from historical estimates derived from 
conventional large scale rodent bioassays26, albeit with significant fluctuations approaching the clinical 
end-point of disease. The significant increase in infectious titre in the last few days of the incubation 
period are unexpected with the change in titre identifiable only as a result of the high precision of SSBA 
and related cell-culture assays which are providing unique insights into the replication of prion isoforms 
during pathogenesis43,44. Levels of MMP-9 in serum provide an indication of BBB integrity and although 
complicated by age-related decline45, sudden elevation towards the clinical end point for prion disease 
Figure 4. Detection of infectivity in blood prior to onset of clinical disease. Detection and quantification 
of infectivity in samples taken at 20, 40, 60, 80, 100, 120, 140 days post infection (dpi) and clinical end-point 
(EP) from CD-1 mice infected with RML prions was achieved using SSBA. Panel (A) shows the correlation 
between m value (n = 3, mean + /− SD) and titred RML-infected brain homogenate when spiked into 
either OFCS/10−4 FVB/N-Prnp0/0 (open circles) or control rodent blood (closed circles). Panel (B) shows 
the calculated LD50 units/ml in whole blood taken from mice culled at each of the 20 day intervals post 
inoculation with RML prions. The m value obtained in the SSBA for each of the time point groups (n = 12, 
mean + /− SD) was converted to LD50 units/ml using the correlation between m value and LD50 units/ml 
for titred RML-infected brain homogenate spiked into control rodent blood as shown in panel (A). The data 
were fitted to the equation m = (B + ((M*L)/(K + L))), where K = a saturation constant (mid-point of the m 
value amplitude), B = background m value and M = m value amplitude or range and L = prion titre.
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(Fig. 5) may indicate a sudden perturbation leading to exchange of prion material between the CNS and 
circulating blood and fluctuations in the concentration of prion disease-related PrP isoforms in blood.
Surprisingly, analysis of the same samples using our DDA assay revealed relatively consistent positive 
signals throughout the RML incubation period (Fig. 3). Positive detection was achieved from the earliest 
time point sampled and could not be ascribed to the detection of residual inoculum as similar signals 
were not observed in the blood of FVB/N-Prnp0/0 mice unable to replicate prions (data not shown), 
and the half-life of prion-infected inocula has previously been shown to be short: 36 hours in rodent 
brain tissue46 and less in cell-culture47. The lack of correlation between DDA reactivity and infectivity 
seen by SSBA indicates DDA is capable of detecting a wider ensemble of abnormal PrP conformers 
associated with prion infection44,48 of which infectivity may only constitute a minority component. Such 
observations are not without precedent and there is increasing evidence to suggest that abnormal PrP 
conformers may be as much as 106-fold more abundant than assayable infectivity49. The ability to detect 
the plethora of abnormal PrP increases the analytical sensitivity of assays and in the case of DDA an 
analytical sensitivity equivalent to a 109-fold dilution of prion-infected brain is sufficient for clinical 
sensitivity at the earliest stages of preclinical prion disease.
Materials and Methods
Research governance. Work with prion-infected samples was conducted in microbiological con-
tainment level 3 facilities with strict adherence to safety protocols. Work with animals was performed in 
accordance with licences approved and granted by the UK Home Office (Project Licences 70/6454 and 
70/7274) and conformed to University College London institutional and ARRIVE guidelines.
A
B [MMP-9] ng ml-1
3
M
ea
n 
O
D 4
50
0
0.5
1.0
1.5
2.0
M
ea
n 
co
rr
ec
te
d 
[M
MP
-9]
 ng
 m
l-1
0
40
80
120
160
RML dpi
20 40 60 80 100 120 140 EP NI
Figure 5. Assessment of blood-brain barrier integrity using MMP-9. Panel (A) shows the correlation 
between the mean OD450 nm readings and the concentration of a standard dilution series of MMP-9 
(ng ml−1). This data was used as a standard curve for converting OD450 nm readings to the concentration of 
MMP-9 in blood. The data in panel (B) display the corrected mean (n = 3, mean + /− SD) concentration of 
MMP-9 in ng ml−1 in pooled whole blood from CD-1 mice inoculated with RML-infected brain homogenate 
at 20 day intervals post inoculation (dpi) until clinical end point of disease (EP). Pooled blood from non-
infected control CD-1 mice is represented as NI.
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Animal experiments. RML or Sc237 prion inocula were prepared as a 10% (w/v) brain homogenate 
in Dulbecco’s phosphate buffered saline lacking Ca2+ or Mg2+ ions (D-PBS)50. Inocula were diluted to 
1% (w/v) with D-PBS and 30 μ l inoculated intracerebrally into experimental animals. Normal CD-1, 
Tga20  mouse or Syrian hamster brain homogenate (1% w/v) was inoculated similarly into control ani-
mals. Animals used were outbred wild-type CD-1 and Tga20 transgenic mice21 (backcrossed to FVB/N 
mice; eightfold over expression of wild-type PrPC), and wild-type Syrian hamsters. Groups of animals 
(female 6–9 weeks old) were inoculated and monitored as described previously43. For the analysis of 
blood from animals at the clinical end point of prion disease, groups of 20 were euthanized and whole 
blood obtained by cardiac puncture for pooling in EDTA tubes. Control materials were obtained in an 
identical manner from age-matched uninoculated animals. To obtain samples from defined time points 
during the incubation period for disease, groups of 30 RML prion inoculated CD-1 mice were euthanized 
at intervals of 20 days and blood pooled into EDTA tubes. The final concentration of EDTA in all samples 
was in the range 6–12 mM. All samples were stored frozen at − 70 °C.
Direct Detection Assay (DDA) for prion infection. The detection of abnormal, disease-specific 
isoforms of the prion protein was performed with modifications to the method previously described19. 
Briefly, experiments involving the exogenous spiking of RML-prion infected brain homogenate into 
whole blood obtained from wild-type CD-1 mice utilised a dilution ratio of 1:10 into assay capture 
buffer (200 mM Tris pH8.4, + 4% w/v BSA + 4% w/v CHAPS + 2× concentration of Complete protease 
inhibitors [Roche, Mannheim, Germany]). Assay read out was in arbitrary chemiluminescence units. 
For comparison of signal levels across the incubation period for prion disease this was normalised to a 
ratio relative to cut-off (RRC) with the cut-off threshold defined as the mean signal from non-infected 
controls + 3× standard deviations from that mean. Hence values greater than one indicate the presence 
of infection.
Exogenous spiked samples were prepared by serial dilution in whole blood from an initial concentra-
tion of 1% w/v brain homogenate.
Exploration of optimal dilutions for varying strains of prions used endogenous blood samples obtained 
from wild-type CD-1, transgenic Tga20 mice21 or Syrian hamsters taken at the clinical end-point of prion 
disease following inoculation with RML or Sc237 prions respectively. Dilutions of 1:1, 1:10 and 1:100 in 
capture buffer were tested and compared to control samples from equivalent uninfected animals.
Detection of infectivity in rodent blood. Infectious RML prions in blood were quantitatively 
detected using the Standard Steel Binding Assay (SSBA)18. Briefly, monofilament Steelex® wires were 
exposed to prion infected samples for 3 hours before being rinsed several times in PBS, and dried. Up 
to 20 wires were placed into each well of a 6-well cluster plate (Corning) and covered with a suspen-
sion of 3 × 105 N2aPK141 cells in 5 ml OFCS (Opti-MEM [Invitrogen] + 10%v/v FCS + 1% w/v peni-
cillin/streptomycin). After culture for 3 days at 37 °C and 5% CO2, the wires with adherent cells were 
transferred into fresh wells containing 1 ml OFCS. The adherent cells were dislodged from the wires by 
vigorous pipetting, collected in a separate tube, and counted. Cells were seeded into wells of 96-well 
plates (Corning) and after 3 days split at a ratio of 1:3 before being split 1:8 into fresh cell culture media 
and grown back to confluence. Two further splits were conducted before transferring a sample of the 
cells to ELISPOT plates for analysis of the number of cells containing PK-resistant PrP and analysis by 
SCEPA41,42.
Endogenous whole blood samples taken from CD-1 mice at defined time points in the incubation 
period for disease were analysed at a 1:10 dilution of blood to buffer (80 μ l blood was diluted in 720 μ l 
capture buffer). To create reference curves wires were exposed to two logarithmic dilution series (10−4 
to 10−10) of RML-infected brain homogenate; one prepared in 10−4 FVB/N-Prnp0/0 brain homogenate in 
OFCS and one in whole blood from uninfected CD-1 mice.
Tissue Culture Infectivity Units and correlation with LD50 Units. SCEPA allows the calculation 
of an ‘m’ value, the average number of infectious units (either in the form of infected cells or prions) 
delivered into a well, using the Poisson equation (P(0) = e−m, where P(0) is the probability of a well remain-
ing uninfected) i.e., non-infected wells/total number of wells. Thus, if a certain amount of a sample were 
to give 9 uninfected wells from a total of 24 receiving sample, then it would contain on average m = ln 
(24/9) = 0.98 or about one infectious unit which, in the case of the wire-mediated assay under standard 
conditions, we have previously defined as a TCIU wire unit (TCIUw)18. We can establish a relationship 
between LD50 units/ml (as established by the mouse bioassay) of the solution to which the wires were 
exposed, and m value by exposing wires to a serial dilution of RML-infected brain homogenate with a 
known rodent titre from bioassay and determining m values resulting from the SSBA.
MMP-9 Assay. The levels of the matrix metalloproteinase-9 (MMP-9) in the blood of CD-1 mice were 
assayed using a commercially available reagent (Mouse total MMP-9 ELISA kit (Molecular Probes)).
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